Company intelligence / Profile preview

Vitesse Biologics

South San Francisco, California, USAvitessehome.com ↗

Ownership: Private
Development stage: Commercial

Overview

Vitesse was established in 2015 as a joint venture between Baxalta/Baxter Ventures, Mayo Clinic, and Velocity Pharmaceutical Development. Its goal was to accelerate the discovery and development of antibody and protein-based therapies for immunology, hematology, and oncology. The first major asset developed under this structure—a BAFF/APRIL dual antagonist for B-cell disorders—was spun out into Thunderbolt Pharma in 2016. No further public pipeline progress has been reported since then.

Therapeutic areas: Immunology
Modalities: AntibodyProtein
Industry: Drug Discovery Services

Partnerships

Baxalta/Baxter VenturesMayo ClinicVelocity Pharmaceutical DevelopmentAstellas Pharma Inc.

Beyond the preview

Go deeper on Vitesse Biologics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vitesse Biologics.

Explore the full profile